Atossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Details
News Market Reaction – ATOS
The recorded move for ATOS in the trading session of this news was +0.67%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces that the Company will take part in the upcoming Cantor Fitzgerald Global Healthcare Conference 2023.
Details of the company's participation are as follows:
- Cantor Fitzgerald Global Healthcare Conference 2023
- Format: Fireside Chat with Chief Executive Officer Steven Quay, M.D., Ph.D.
- Date and Time: Thursday, September 28th at 9:10 A.M. ET
- Location: New York, NY
Interested parties may access the live webcast of the fireside chat by visiting the Investors section of the Atossa website at https://investors.atossatherapeutics.com. The webcast replay will be archived on the Atossa website for 90 days following the conclusion of the event.
About Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. For more information, please visit www.atossatherapeutics.com.
Contact:
Eric Van Zanten
VP, Investor and Public Relations
610-529-6219
eric.vanzanten@atossainc.com